Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
Equillium Q3 EPS $(0.04) Beats $(0.05) Estimate
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Equillium Announces Poster Presentations at the 7th International AHR Conference
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target
EQ Inc. Reports Second Quarter 2026 Financial Results
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Equillium: The Market Seems To Have Already Priced In Phase 1 Success
Integrated Rewards Expands Offer Network into Everyday Spend Categories Like Fuel, Hotel and Grocery
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504
EQ Works Expands ClearLake Platform with AI-Powered Audience Segments
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease - Slideshow
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.